The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Helius Medical Technologies Announces Extension of Agreement with US Army
Sep. 13, 2017 09:25AM PST
Medical Device InvestingHelius Medical Technologies announced its subsidiary NeuroHabilitation executed an extension to its research and development agreement with the US Army Medical Research and Materiel Command through 2018.
Helius Medical Technologies (TSX:HSM; OTCQB:HSDT) announced its subsidiary NeuroHabilitation executed an extension to its research and development agreement with the US Army Medical Research and Materiel Command through 2018.
As quoted in the press release:
[NeuroHabilitation] extended the deadline for commercialization of the PoNS Therapy to December 31, 2021.
The CRADA partners Helius and the USAMRMC in the clinical development and commercialization of the Company’s Portable Neuromodulation Stimulator (PoNS) device, a non-invasive brain stimulation device, currently being developed for the treatment of chronic balance disorder in patients with mild to moderate traumatic brain injury.
The CRADA is also intended to support the development of other potential indications of the device, relevant to injured service members who have suffered a traumatic brain injury, such as treating tinnitus, post-traumatic stress, sleep disturbances or chronic pain.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.